Press Releases
  Date Title View
Aug 3, 2016
SAN DIEGO, Aug. 03, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced financial results for the quarter and six months ended June 30, 2016, and provided updates on its clinical de...
Jul 27, 2016
SAN DIEGO, July 27, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that it will report financial results for the second quarter ended June 30, 2016, after the market close on W...
Jun 14, 2016
SAN DIEGO, June 14, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced its planned participation in the JMP Securities Life Sciences Conference on Tuesday, June 21, 2016, in New York. The company is scheduled to engage in a "fireside chat" with a JMP Securities analyst and expects to host meeting...
May 5, 2016
SAN DIEGO, May 05, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced financial results for the first quarter ended March 31, 2016, and provided updates on its development programs...
May 4, 2016
- Continued Directional Improvements in Key Measures of Liver Function after Six Months - - First Drug to Demonstrate Liver Function Benefit in Patients with NASH Cirrhosis - - Conference Call and Webcast Presentat...
Apr 28, 2016
SAN DIEGO, April 28, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that it will report financial results for the first quarter ended March 31, 2016, before the market opens ...
Apr 18, 2016
SAN DIEGO, April 18, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced today the delivery of a late breaker oral presentation at The International Liver Congress™ 2016, the Annual Meeting of the European Association for the Study of the Liver (EASL) in Barcelona, Spain, April 13-17, 2016. The pr...
Apr 15, 2016
SAN DIEGO, April 15, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced that a poster addressing results in both ex vivo cell culture and in vivo mouse models of hepatocellular carcinoma with IDN-7314, an orally active pan-caspase inhibitor, is being presented today at The Internat...
Apr 5, 2016
SAN DIEGO, April 05, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced its scheduled presentation to provide an overview of the company's programs and outlook at the 15th Annual Needham Healthcare Conference on Wednesday, April 13, 2016, at 9:20 a.m. ET, in New York.  An audio we...
Apr 4, 2016
SAN DIEGO, April 04, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced the appointment of Edward F. Smith III, Ph.D., as Senior Vice President, Regulatory Affairs and Quality Assu...
FirstPrevious
3
...
NextLast
= add release to Briefcase